Skip to main content
Top
Published in: Clinical Rheumatology 11/2016

01-11-2016 | Original Article

Gastrointestinal comorbidities in patients with psoriatic arthritis

Authors: Ariel Zohar, Arnon Dov Cohen, Haim Bitterman, Ilan Feldhamer, Sari Greenberg-Dotan, Idit Lavi, Doron Comanesther, Erez Batat, Devy Zisman

Published in: Clinical Rheumatology | Issue 11/2016

Login to get access

Abstract

Comorbidities associated with psoriatic arthritis (PsA) include cardiovascular diseases, diabetes mellitus, and obesity. This study evaluated the association between PsA and common gastrointestinal (GI) diseases. A retrospective study was performed in Israel’s largest health care provider database between 2002 and 2013. 3161 PsA patients were matched for age and sex with 31610 randomly selected patients. We searched these patients’ records for the presence of peptic ulcer disease (PUD), reflux esophagitis, Crohn’s disease, ulcerative colitis, irritable bowel syndrome (IBS) and celiac disease. T-test was used to compare continuous variables and a Chi-square test was used for categorical variables. Multivariate logistic regression models were used to assess the association between PsA and GI comorbidities. PsA was associated with Crohn’s disease (OR 2.4, 95 %CI: 1.75–3.32, p < 0.0001), ulcerative colitis (OR 2.1, 95 %CI: 1.33–3.26, p = 0.001), reflux esophagitis (OR 1.6, 95 %CI: 1.44–1.78, p < 0.0001), PUD (OR 1.5, 95 %CI: 1.31–1.63, p < 0.0001) and IBS (OR 1.4, 95 %CI: 1.01–1.86, p = 0.045). After controlling for known risk factors, the association remained significant between PsA and Crohn’s disease (OR 2.2, 95 %CI: 1.59–3.03, p < 0.0001), ulcerative colitis (OR 1.9, 95 %CI: 1.21–3.00, p = 0.005), reflux esophagitis (OR 1.5, 95 %CI: 1.31–1.63, p < 0.0001), and PUD (OR 1.3, 95 %CI: 1.12–1.47, p < 0.0001). No significant association was found between PsA and celiac disease. In the current study PsA was associated with gastrointestinal morbidities including Crohn’s disease, ulcerative colitis, PUD and IBS. Physicians treating patients with PsA should be aware of these associations.
Literature
2.
go back to reference Oliveira M de FSP de, Rocha B de O, Duarte GV (2015) Psoriasis: classical and emerging comorbidities. Ann Bras Dermatol 90:9–20. doi: 10.1590/abd1806–4841.20153038 Oliveira M de FSP de, Rocha B de O, Duarte GV (2015) Psoriasis: classical and emerging comorbidities. Ann Bras Dermatol 90:9–20. doi: 10.1590/abd1806–4841.20153038
6.
go back to reference Helliwell PS (2004) Relationship of psoriatic arthritis with the other spondyloarthropathies. Curr Opin Rheumatol 16:344–349CrossRefPubMed Helliwell PS (2004) Relationship of psoriatic arthritis with the other spondyloarthropathies. Curr Opin Rheumatol 16:344–349CrossRefPubMed
8.
go back to reference Levine JS, Burakoff R (2011) Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol (N Y) 7:235–241 Levine JS, Burakoff R (2011) Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol (N Y) 7:235–241
11.
go back to reference Ciccia F, Guggino G, Ferrante A, et al. (2016) Interleukin-9 overexpression and Th9 polarization characterize the inflamed gut, the synovial tissue, and the peripheral blood of patients with psoriatic arthritis. Arthritis & Rheumatology (Hoboken, NJ) 68:1922–1931. doi:10.1002/art.39649 CrossRef Ciccia F, Guggino G, Ferrante A, et al. (2016) Interleukin-9 overexpression and Th9 polarization characterize the inflamed gut, the synovial tissue, and the peripheral blood of patients with psoriatic arthritis. Arthritis & Rheumatology (Hoboken, NJ) 68:1922–1931. doi:10.​1002/​art.​39649 CrossRef
13.
go back to reference Cohen AD, Weitzman D, Birkenfeld S, Dreiher J (2010) Psoriasis associated with hepatitis C but not with hepatitis B. Dermatology (Basel) 220:218–222. doi:10.1159/000286131 CrossRef Cohen AD, Weitzman D, Birkenfeld S, Dreiher J (2010) Psoriasis associated with hepatitis C but not with hepatitis B. Dermatology (Basel) 220:218–222. doi:10.​1159/​000286131 CrossRef
20.
21.
go back to reference Scher JU, Ubeda C, Artacho A, et al. (2015) Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis & Rheumatology (Hoboken, NJ) 67:128–139. doi:10.1002/art.38892 CrossRef Scher JU, Ubeda C, Artacho A, et al. (2015) Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis & Rheumatology (Hoboken, NJ) 67:128–139. doi:10.​1002/​art.​38892 CrossRef
23.
go back to reference Mielants H, De Vos M, Cuvelier C, Veys EM (1996) The role of gut inflammation in the pathogenesis of spondyloarthropathies. Acta Clin Belg 51:340–349CrossRefPubMed Mielants H, De Vos M, Cuvelier C, Veys EM (1996) The role of gut inflammation in the pathogenesis of spondyloarthropathies. Acta Clin Belg 51:340–349CrossRefPubMed
24.
go back to reference Mielants H, Veys EM, De Vos M, et al. (1995) The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol 22:2266–2272PubMed Mielants H, Veys EM, De Vos M, et al. (1995) The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol 22:2266–2272PubMed
25.
go back to reference Mielants H, Veys EM, Cuvelier C, et al. (1995) The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol 22:2273–2278PubMed Mielants H, Veys EM, Cuvelier C, et al. (1995) The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol 22:2273–2278PubMed
26.
go back to reference Mielants H, Veys EM, Cuvelier C, et al. (1995) The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 22:2279–2284PubMed Mielants H, Veys EM, Cuvelier C, et al. (1995) The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 22:2279–2284PubMed
27.
go back to reference Schatteman L, Mielants H, Veys EM, et al. (1995) Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopic study. J Rheumatol 22:680–683PubMed Schatteman L, Mielants H, Veys EM, et al. (1995) Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopic study. J Rheumatol 22:680–683PubMed
29.
go back to reference Teahon K, Smethurst P, Levi AJ, et al. (1992) Intestinal permeability in patients with Crohn’s disease and their first degree relatives. Gut 33:320–323CrossRefPubMedPubMedCentral Teahon K, Smethurst P, Levi AJ, et al. (1992) Intestinal permeability in patients with Crohn’s disease and their first degree relatives. Gut 33:320–323CrossRefPubMedPubMedCentral
30.
go back to reference Vaile JH, Meddings JB, Yacyshyn BR, et al. (1999) Bowel permeability and CD45RO expression on circulating CD20+ B cells in patients with ankylosing spondylitis and their relatives. J Rheumatol 26:128–135PubMed Vaile JH, Meddings JB, Yacyshyn BR, et al. (1999) Bowel permeability and CD45RO expression on circulating CD20+ B cells in patients with ankylosing spondylitis and their relatives. J Rheumatol 26:128–135PubMed
32.
go back to reference Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD (2011) Gastrointestinal manifestations in systemic autoimmune diseases. Maedica (Buchar) 6:45–51 Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD (2011) Gastrointestinal manifestations in systemic autoimmune diseases. Maedica (Buchar) 6:45–51
33.
go back to reference Pellicano R (2014) Gastrointestinal damage by non-steroidal anti-inflammatory drugs: updated clinical considerations. Minerva Gastroenterol Dietol 60:255–261PubMed Pellicano R (2014) Gastrointestinal damage by non-steroidal anti-inflammatory drugs: updated clinical considerations. Minerva Gastroenterol Dietol 60:255–261PubMed
35.
go back to reference Szodoray P, Alex P, Chappell-Woodward CM, et al. (2007) Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology (Oxford) 46:417–425. doi:10.1093/rheumatology/kel306 CrossRef Szodoray P, Alex P, Chappell-Woodward CM, et al. (2007) Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology (Oxford) 46:417–425. doi:10.​1093/​rheumatology/​kel306 CrossRef
40.
go back to reference Lubrano E, Iovino P, Tremolaterra F, et al. (2001) Fibromyalgia in patients with irritable bowel syndrome. An association with the severity of the intestinal disorder. Int J Color Dis 16:211–215CrossRef Lubrano E, Iovino P, Tremolaterra F, et al. (2001) Fibromyalgia in patients with irritable bowel syndrome. An association with the severity of the intestinal disorder. Int J Color Dis 16:211–215CrossRef
41.
go back to reference Salaffi F, De Angelis R, Carotti M, et al. (2014) Fibromyalgia in patients with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity. Rheumatol Int 34:1103–1110. doi:10.1007/s00296-014-2955-9 PubMed Salaffi F, De Angelis R, Carotti M, et al. (2014) Fibromyalgia in patients with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity. Rheumatol Int 34:1103–1110. doi:10.​1007/​s00296-014-2955-9 PubMed
Metadata
Title
Gastrointestinal comorbidities in patients with psoriatic arthritis
Authors
Ariel Zohar
Arnon Dov Cohen
Haim Bitterman
Ilan Feldhamer
Sari Greenberg-Dotan
Idit Lavi
Doron Comanesther
Erez Batat
Devy Zisman
Publication date
01-11-2016
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 11/2016
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3374-y

Other articles of this Issue 11/2016

Clinical Rheumatology 11/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine